VLS Valneva SE

VALNEVA - Declaration of shares and voting rights - February 28, 2023

VALNEVA - Declaration of shares and voting rights - February 28, 2023

VALNEVA

Declaration of shares and voting rights

February 28, 2023

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: March 6, 2023

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



138,346,968



ordinary shares with a par value of €0.15 each





160,955,318Double voting rights granted on 3,075 ordinary shares



 



Sale of 50 shares with double voting rights
Between February 10 & February 25, 2023



 



February 7, 2023
160,830,996

  

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
06/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Valneva to Report Full Year 2025 Consolidated Financial Results on Mar...

Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026  Lyon (France), March 9, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, March 18, 2026. The Company will host a live webcast beginning at 3 p.m. CET/10 a.m. EDT to discuss the financial results and provide a business update.  The live webcast will be accessible on the Company’s website and made available as an archive after the event concludes. Please refer to this link:  .  About Valne...

 PRESS RELEASE

Valneva publiera ses résultats financiers consolidés 2025 le 18 mars 2...

Valneva publiera ses résultats financiers consolidés 2025 le 18 mars 2026 Lyon (France), le 9 mars 2026 – (Nasdaq: VALN; Euronext Paris: VLA, société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers pour l’exercice 2025 le mercredi 18 mars 2026. La Société tiendra une webconférence en direct à partir de 15h00 CET sur ses résultats au cours de laquelle elle fera également un point sur son activité. La webconférence sera accessible via le site internet de la Société et disponible en replay après l’évènement via le lien suivant : . À propos de V...

 PRESS RELEASE

VALNEVA Declaration of shares and voting rights: February 28, 2026

VALNEVA Declaration of shares and voting rights: February 28, 2026 VALNEVA Declaration of shares and voting rights February 28, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: March 6, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this c...

 PRESS RELEASE

VALNEVA Déclaration d’actions et de droits de vote : 28 février 2026

VALNEVA Déclaration d’actions et de droits de vote : 28 février 2026 VALNEVA Déclaration d’actions et de droits de vote 28 février 2026__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon Marché réglementé Euronext Paris - Compartiment B Date de la déclaration : 6 mars 2026 Nombre d’actions composant le capital de ValnevaNombre total de droits de vote incluant les droits de vote suspendus*Origine de la variation...

 PRESS RELEASE

Valneva to Participate in Upcoming Investor Conferences

Valneva to Participate in Upcoming Investor Conferences Lyon (France), March 2, 2026 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Buhler will discuss the Company’s key value drivers and upcoming catalysts, including the topline Phase 3 data readout for VLA15, the Company’s Lyme disease vaccine candidate, which partner Pfizer expects to report in the first half of 2026. The TD Cowen presenta...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch